Daewon reports up to 3.14 times the exposure of Rybelsus 14 mg across two studies of 18 and 19 people, and it plans a Korean phase 1 filing in 2027.
Recap by typeshit. Full story at Korea Biomedical Review.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
In an ANI broadcast promo, Batra says users may lose muscle mass and calls keto unsustainable over the long term.
Koufakis and colleagues pooled trial data in Advances in Therapy. In the SEMALEAN study, handgrip strength rose 4.5 kg at 12 months on semaglutide.
Loading…